Protalix BioTherapeutics (PLX) Q3 Investor Summit Group Virtual Conference 2025 earnings summary

Technology and business model

• Utilizes plant cell expression technology for complex human proteins, offering cost and safety advantages over mammalian cell systems.

• Manufacturing is scalable, conducted at room temperature, and avoids viral contamination risks.

• Two FDA- and EMA-approved drugs: Elelyso (Gaucher) and Elfabrio (Fabry), both commercialized via partners.

• Early-stage pipeline includes PRX-115 for severe gout, leveraging proprietary PEGylation technology.

Commercial portfolio and partnerships

• Elelyso generates $22–24 million annually from Pfizer and Brazil, with the Pfizer agreement expiring in October 2030.

• Elfabrio targets the growing Fabry market, expected to reach $3.2 billion by 2030, with Chiesi as the global commercialization partner.

• Royalty rates for Elfabrio range from 15–40% depending on geography, plus up to $100 million in milestone payments.

• Chiesi is projected to capture 15–20% of the Fabry market, potentially yielding $100–120 million in annual royalties.

Market dynamics and growth strategy

• Revenue recognition for Elfabrio occurs upon inventory transfer to Chiesi, not end-market sales.

• Chiesi's inventory management can cause quarterly sales fluctuations, but patient uptake and market share are increasing.

• EMA review is underway for a once-monthly dosing regimen for Elfabrio, with a decision expected by mid to late October.

• Approval of monthly dosing could increase Chiesi's market share to 25–33%.